^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    S100A8 elevation

    i
    Other names: S100A8, S100 Calcium Binding Protein A8, Migration Inhibitory Factor-Related Protein 8, Leukocyte L1 Complex Light Chain, Urinary Stone Protein Band A, Calprotectin L1L Subunit, Cystic Fibrosis Antigen, Protein S100-A8, Calgranulin A, CAGA, CFAG, MRP8, S100 Calcium-Binding Protein A8 (Calgranulin A), S100 Calcium-Binding Protein A8, Calgranulin-A, 60B8AG, CP-10, MA387, MRP-8, CGLA, L1Ag, MIF, NIF
    Entrez ID:
    6279
    Related biomarkers:
    Expression
    Others
    12ms
    Evaluation of S100A8/A9 and neutrophils as prognostic markers in metastatic melanoma patients under immune-checkpoint inhibition. (PubMed, Transl Oncol)
    By enhancing monitoring and prognosis assessment, these biomarkers contribute to refining treatment strategies, ultimately improving patient care and outcomes. This research bridges gaps in understanding melanoma response mechanisms and highlights avenues for further investigation into immune-related markers, fostering advancements in precision medicine for melanoma patients.
    Journal • Checkpoint inhibition • IO biomarker • Metastases
    |
    S100A8 (S100 Calcium Binding Protein A8)
    |
    S100A8 elevation
    12ms
    A new perspective on macrophage-targeted drug research: the potential of KDELR2 in bladder cancer immunotherapy. (PubMed, Front Immunol)
    The findings suggested that patients with high KDELR2 expression might benefit from immune checkpoint therapy. KDELR2 was also shown to enhance bladder cancer cell proliferation, invasion, and migration, highlighting it as a promising target for macrophage-focused drug development.
    Journal • IO biomarker
    |
    CD74 (CD74 Molecule) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • S100A8 (S100 Calcium Binding Protein A8)
    |
    S100A8 elevation • S100A8 expression
    almost2years
    S100A8 is a prognostic signature and associated with immune response in diffuse large B-cell lymphoma. (PubMed, Front Oncol)
    Inhibition of S100A8 could promote cell apoptosis and suppress tumor growth. Meanwhile, S100A8 has the potential to be a promising immunotherapeutic target for patients with DLBCL.
    Journal • IO biomarker
    |
    S100A8 (S100 Calcium Binding Protein A8) • IL17A (Interleukin 17A)
    |
    S100A8 elevation • S100A8 expression
    almost2years
    S100A8/A9 as a risk factor for breast cancer negatively regulated by DACH1. (PubMed, Biomark Res)
    S100A8/A9 is remarkedly increased in basal-like and Her2-overexpressed subtypes, predicting poor prognosis of breast cancer patients. Tumor suppressor DACH1 inhibits S100A8/A9 expression. The combination of S100A8/A9 and DACH1 predicted the overall survival of breast cancer patients more preciously.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • S100A8 (S100 Calcium Binding Protein A8) • S100A9 (S100 Calcium Binding Protein A9) • DACH1 (Dachshund Family Transcription Factor 1)
    |
    HER-2 positive • HER-2 overexpression • S100A8 elevation • S100A8 expression